ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 248796" data-attributes="member: 3"><p><strong>Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study</strong></p><p></p><p>INTRODUCTION</p><p>Hypogonadism is prevalent during opioid treatment and low testosterone concentrations are associated with cardiovascular disease. The effect of testosterone replacement therapy (TRT) on the coagulation system in men with hypogonadism is not clarified. We investigate effects of TRT on the tissue factor (TF) and contact activation pathways of coagulation in opioid treated men.</p><p></p><p></p><p>MATERIALS AND METHODS</p><p>Double-blinded, placebo-controlled study in 37 men with total testosterone < 12 nmol/l randomized to 24 weeks of testosterone injections (n = 17) or placebo (n = 20). Variables of the coagulation system were analysed at baseline and after 24 weeks. Measurements included the TF pathway (endogenous thrombin potential (ETP), peak thrombin), the contact activation pathway (endogenous kallikrein potential (EKP), peak kallikrein), coagulation factors (FVII, FX, prothrombin, FXII), and inhibitors (tissue factor pathway inhibitor (TFPI), protein C, protein S, antithrombin, C1 esterase inhibitor (C1inh)). Between-group differences at 24 weeks were determined with analysis of covariance. Within-group changes in TRT and placebo were analysed with paired t-test.</p><p></p><p></p><p>RESULTS</p><p>Between-group differences at 24 weeks were observed for ETP (p = 0.036), FVII (p = 0.044), FX (p = 0.015), prothrombin (p = 0.003), protein C (p = 0.004), and protein S (p = 0.038). Within the TRT group, ETP, peak thrombin, FVII, FX, prothrombin, TFPI, protein C, FXII, and C1inh decreased and protein S increased (all p < 0.05). Within the placebo group, coagulation outcomes were unchanged.</p><p></p><p></p><p>CONCLUSION</p><p>TRT affects the coagulation system in an anticoagulant direction through suppressed TF pathway in men with opioid-induced hypogonadism. </p><p></p><p>Source: <a href="https://pubmed.ncbi.nlm.nih.gov/36752832/" target="_blank">Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study - PubMed</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 248796, member: 3"] [B]Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study[/B] INTRODUCTION Hypogonadism is prevalent during opioid treatment and low testosterone concentrations are associated with cardiovascular disease. The effect of testosterone replacement therapy (TRT) on the coagulation system in men with hypogonadism is not clarified. We investigate effects of TRT on the tissue factor (TF) and contact activation pathways of coagulation in opioid treated men. MATERIALS AND METHODS Double-blinded, placebo-controlled study in 37 men with total testosterone < 12 nmol/l randomized to 24 weeks of testosterone injections (n = 17) or placebo (n = 20). Variables of the coagulation system were analysed at baseline and after 24 weeks. Measurements included the TF pathway (endogenous thrombin potential (ETP), peak thrombin), the contact activation pathway (endogenous kallikrein potential (EKP), peak kallikrein), coagulation factors (FVII, FX, prothrombin, FXII), and inhibitors (tissue factor pathway inhibitor (TFPI), protein C, protein S, antithrombin, C1 esterase inhibitor (C1inh)). Between-group differences at 24 weeks were determined with analysis of covariance. Within-group changes in TRT and placebo were analysed with paired t-test. RESULTS Between-group differences at 24 weeks were observed for ETP (p = 0.036), FVII (p = 0.044), FX (p = 0.015), prothrombin (p = 0.003), protein C (p = 0.004), and protein S (p = 0.038). Within the TRT group, ETP, peak thrombin, FVII, FX, prothrombin, TFPI, protein C, FXII, and C1inh decreased and protein S increased (all p < 0.05). Within the placebo group, coagulation outcomes were unchanged. CONCLUSION TRT affects the coagulation system in an anticoagulant direction through suppressed TF pathway in men with opioid-induced hypogonadism. Source: [URL="https://pubmed.ncbi.nlm.nih.gov/36752832/"]Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study - PubMed[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Expert Interviews
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top